Axogen, Inc. filed an amendment to its Form 8-K to include the Agreement and Plan of Merger with BioCircuit Technologies, Inc., and a corrected investor presentation. The company agreed to acquire BioCircuit for $200 million in cash, subject to customary adjustments. The transaction is expected to close in Q4 2026 and will be funded substantially through net proceeds from an equity offering. BioCircuit commercializes NerveTape, the first FDA-cleared device for sutureless nerve repair, which generated approximately $11 million in revenue in 2025 and runs at a ~$24 million annualized rate as of Q2 2026. Axogen anticipates the acquisition to be accretive to revenue growth and adjusted EBITDA margins in Year 1 while maintaining free cash flow positivity. Axogen, Inc. operates in the medical device industry, specializing in peripheral nerve repair technologies.
